# CEL Sci Corp: overview CVM · NYSE · CIK 725363 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30 Pages: [Overview](/companies/cvm.md) · [Financials](/companies/cvm/financials.md) · [Filings](/companies/cvm/filings.md) · [Insiders](/companies/cvm/insiders.md) Latest reported revenue: [$17.4k](/filings/0001654954-17-011501.md) for Q3 FY2017, three months to 2017-06-30, from the 10-Q/A filed Dec 11, 2017 (XBRL us-gaap:Revenues, accession 0001654954-17-011501). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(3.25)](/filings/0001654954-26-001319.md) | [(2.33)](/filings/0001654954-26-005005.md) | [(1.36)](/filings/0001654954-26-007657.md) | not reported | [(0.68)](/filings/0001654954-26-001319.md) | [(0.67)](/filings/0001654954-26-005005.md) | [(0.47)](/filings/0001654954-26-007657.md) | | Free cash flow | $k | [(4,836) d](/filings/0001654954-25-014303.md) | [(4,173)](/filings/0001654954-26-001319.md) | [(4,370) d](/filings/0001654954-26-005005.md) | [(3,940) d](/filings/0001654954-26-007657.md) | [(4,676) d](/filings/0001654954-25-014303.md) | [(4,022)](/filings/0001654954-26-001319.md) | [(4,022) d](/filings/0001654954-26-005005.md) | [(4,031) d](/filings/0001654954-26-007657.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.90)](/filings/0001654954-22-016959.md) | [(0.87)](/filings/0001654954-22-016959.md) | [(0.73)](/filings/0001654954-25-000288.md) | [(15.31)](/filings/0001654954-25-014303.md) | [(6.27)](/filings/0001654954-25-014303.md) | | Free cash flow | $m | [(27.8)](/filings/0001654954-22-016959.md) | [(18.9)](/filings/0001654954-23-015877.md) | [(23.2)](/filings/0001654954-25-000288.md) | [(18.9)](/filings/0001654954-25-014303.md) | [(17.2)](/filings/0001654954-25-014303.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cvm/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $595.4k | 572,460 | | Added +536,570 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $564.8k | 543,079 | | Added +299,434 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $206.4k | 198,500 | | New +198,500 | | [MAI Capital Management](/funds/1040197.md) | 2026-06-30 | $112.6k | 108,280 | | Added +17,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $91.8k | 88,200 | | Added +2,889 | | [COMMONWEALTH EQUITY SERVICES, LLC](/funds/312272.md) | 2026-06-30 | $53.5k | 51,434 | | Added +33,812 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $51.0k | 49,036 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $45.0k | 43,261 | | Unchanged | | [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $42.6k | 40,916 | | Reduced −81 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $37.9k | 36,458 | | New +36,458 | ## Recent filings [All 1,210 filings](/companies/cvm/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-17 | 13:05 ET | [8-K](/filings/0001654954-26-007691.md) | 5.07 Shareholder vote results | 0001654954-26-007691 | | 2026-08-14 | 20:16 ET | [10-Q](/filings/0001654954-26-007657.md) | Quarterly report, period 2026-06-30 | 0001654954-26-007657 | | 2026-07-02 | 21:01 ET | [DEF 14A](/filings/0001654954-26-006496.md) | Proxy statement, period 2026-06-23 | 0001654954-26-006496 | | 2026-06-16 | 21:03 ET | [8-K](/filings/0001654954-26-006015.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001654954-26-006015 | | 2026-05-15 | 21:00 ET | [10-Q](/filings/0001654954-26-005005.md) | Quarterly report, period 2026-03-31 | 0001654954-26-005005 | | 2026-05-14 | 21:16 ET | [8-K](/filings/0001654954-26-004910.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001654954-26-004910 | | 2026-05-13 | 20:44 ET | [8-K](/filings/0001654954-26-004823.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001654954-26-004823 | | 2026-05-01 | 21:00 ET | [S-1/A](/filings/0001654954-26-004295.md) | Registration statement, amended | 0001654954-26-004295 | | 2026-04-17 | 21:07 ET | [S-1](/filings/0001654954-26-003679.md) | Registration statement | 0001654954-26-003679 | | 2026-02-17 | 22:01 ET | [10-Q](/filings/0001654954-26-001319.md) | Quarterly report, period 2025-12-31 | 0001654954-26-001319 | ## Latest annual report [Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001654954-25-014303.md), filed Dec 29, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 725363 - Tickers: CVM - Exchange: NYSE - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: CO - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.